Mainz Biomed B.V.(MYNZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MYNZ Mainz Biomed B.V.

Market Closed 12-05 16:00:00 EST

1.16

-0.01

-0.85%

盘后1.16

+0.00+0.01%

19:31 EST

High1.20	Low1.16	Vol101.17K
Open1.19	D1 Closing1.17	Amplitude3.42%
Mkt Cap9.96M	Tradable Cap9.44M	Total Shares8.58M
T/O119.26K	T/O Rate1.24%	Tradable Shares8.14M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MYNZ","market":"US","secType":"STK","nameCN":"Mainz Biomed B.V.","latestPrice":1.16,"timestamp":1764968400000,"preClose":1.17,"halted":0,"volume":101170,"hourTrading":{"tag":"盘后","latestPrice":1.1601,"preClose":1.16,"latestTime":"19:31 EST","volume":4849,"amount":5625.8665,"timestamp":1764981067064},"delay":0,"floatShares":8138099,"shares":8583900,"eps":-22.360981,"marketStatus":"Market Closed","change":-0.01,"latestTime":"12-05 16:00:00 EST","open":1.19,"high":1.2,"low":1.16,"amount":119259.833371,"amplitude":0.034188,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-22.360981,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765184400000},"marketStatusCode":7,"adr":0,"listingDate":1635998400000,"exchange":"NASDAQ","adjPreClose":1.17,"preHourTrading":{"tag":"盘前","latestPrice":1.17,"preClose":1.17,"latestTime":"09:28 EST","volume":3891,"amount":4510.9557537,"timestamp":1764944884040},"postHourTrading":{"tag":"盘后","latestPrice":1.1601,"preClose":1.16,"latestTime":"19:31 EST","volume":4849,"amount":5625.8665,"timestamp":1764981067064},"volumeRatio":0.624134773929546},"requestUrl":"/m/hq/s/MYNZ/tweets","defaultTab":"tweets","newsList":[{"id":"2588053403","title":"Mainz Biomed NV Partners with DoctorBox to Offer Home DNA Colorectal Cancer Test","url":"https://stock-news.laohu8.com/highlight/detail?id=2588053403","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588053403?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:02","pubTimestamp":1764680526,"startTime":"0","endTime":"0","summary":"Mainz Biomed N.V., a molecular genetics diagnostic company specializing in early cancer detection, has announced a partnership with DoctorBox, one of Germany's leading digital health platforms. Through this collaboration, Mainz Biomed's DNA-based colorectal cancer screening test, ColoAlert, will be added to DoctorBox's portfolio of preventive healthcare services. The partnership aims to expand access to at-home colorectal cancer screening, with laboratory analysis provided by the European Oncology Lab. This move supports Mainz Biomed's European growth strategy and highlights the increasing role of digital solutions in preventive medicine.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mainz Biomed NV published the original content used","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDLb27KLW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","IE00B64PRP62.GBP","NDAQ","LU2210150020.SGD","LU2210149790.SGD","BK4588","MYNZ","LU2095319765.USD","BK4585","IE00B3QW5Z07.USD","BK4139","IE00BGHQF748.EUR","BK4112","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2584937226","title":"Mainz Biomed Signs MOU with OncoVanguard8 to Launch ColoAlert in South America","url":"https://stock-news.laohu8.com/highlight/detail?id=2584937226","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584937226?lang=en_us&edition=fundamental","pubTime":"2025-11-18 21:03","pubTimestamp":1763470996,"startTime":"0","endTime":"0","summary":"Mainz Biomed NV announced the signing of a Memorandum of Understanding  with OncoVanguard8 to introduce its DNA-based colorectal cancer screening test, ColoAlert, to South America, beginning with Peru. The agreement outlines commercial, legal, and regulatory terms, as well as the go-to-market strategy for the initial territory. The companies aim to finalize a distribution agreement in the coming weeks.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mainz Biomed NV published the original content used to generate this news brief via GlobeNewswire  on November 18, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nNDL83B0n0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","LU0314104364.USD","BK4112","BK4139","MYNZ","LU2210149790.SGD","BK4588","IE00BKPKM429.USD","BK4585","IE00B64PRP62.GBP","LU2095319765.USD","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","NDAQ"],"gpt_icon":0},{"id":"2582797233","title":"Mainz Biomed NV Showcases Cancer Detection Solutions at MEDICA","url":"https://stock-news.laohu8.com/highlight/detail?id=2582797233","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582797233?lang=en_us&edition=fundamental","pubTime":"2025-11-12 21:02","pubTimestamp":1762952527,"startTime":"0","endTime":"0","summary":"Mainz Biomed NV will participate in MEDICA 2025, one of the world's leading healthcare trade shows, taking place from November 17 to 20, 2025, in Düsseldorf, Germany. The company will showcase its flagship product, ColoAlert, a molecular stool-based screening test for early detection of colorectal cancer, along with other upcoming diagnostic solutions for early-stage cancer diagnosis.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mainz Biomed NV published the original content used to generate this news brief via GlobeNewswire  on November 12, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL5qdMTG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","LU0314104364.USD","BK4585","LU2095319765.USD","LU2210150020.SGD","MYNZ","IE00B64PRP62.GBP","BK4588","LU2210149790.SGD","BK4139","NDAQ","IE00BKPKM429.USD","IE00BGHQF748.EUR","BK4112"],"gpt_icon":0},{"id":"2582879240","title":"Mainz Biomed NV to Attend Annual Gastroenterological Working Group of Rhineland-Palatinate Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2582879240","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582879240?lang=en_us&edition=fundamental","pubTime":"2025-11-10 21:04","pubTimestamp":1762779865,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mainz Biomed NV published the original content used to generate this news brief via GlobeNewswire  on November 10, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL1c2qcn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","LU2210150020.SGD","BK4112","BK4588","IE00B3QW5Z07.USD","LU2095319765.USD","IE00BGHQF748.EUR","MYNZ","LU2210149790.SGD","NDAQ","IE00B64PRP62.GBP","IE00BKPKM429.USD","BK4139","BK4585"],"gpt_icon":0},{"id":"2575778778","title":"Mainz Biomed NV to Attend Maxim Growth Summit in New York City","url":"https://stock-news.laohu8.com/highlight/detail?id=2575778778","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575778778?lang=en_us&edition=fundamental","pubTime":"2025-10-15 21:01","pubTimestamp":1760533287,"startTime":"0","endTime":"0","summary":"Mainz Biomed NV, a molecular genetics diagnostic company specializing in early cancer detection, will attend the 2025 Maxim Growth Summit on October 22-23, 2025, at The Hard Rock Hotel NYC. The company will participate in one-on-one meetings with institutional investors and senior Maxim analysts during the event.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mainz Biomed NV published the original content used to generate this news brief via GlobeNewswire  on October 15, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251015:nNDL2lS8p0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU0314104364.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","MYNZ","BK4139","NDAQ","LU2095319765.USD","LU2210149790.SGD","BK4588","IE00BKPKM429.USD","LU2210150020.SGD","BK4112","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2573250289","title":"Mainz Biomed NV Reports Positive Results for BloodBased Pancreatic Cancer Screening Test in Feasibility Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2573250289","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573250289?lang=en_us&edition=fundamental","pubTime":"2025-10-08 21:00","pubTimestamp":1759928436,"startTime":"0","endTime":"0","summary":"Mainz Biomed NV has announced positive topline results from a feasibility study evaluating a non-invasive blood-based screening test for the early detection of pancreatic cancer. The study assessed 18 proprietary mRNA biomarkers and identified a panel that demonstrated 100% sensitivity and 95% specificity in distinguishing pancreatic cancer patients from healthy controls within a 30-subject cohort. The results confirmed the clinical accuracy and utility of the biomarkers, and the company plans to initiate a larger clinical study using banked retrospective samples to further evaluate biomarker performance across different stages of pancreatic cancer. This future study will utilize next-generation sequencing technologies and is part of Mainz Biomed's broader strategy to develop accessible molecular diagnostics for early cancer detection.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and time","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251008:nNDL1S70Qx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","LU2210150020.SGD","LU2095319765.USD","IE00BGHQF748.EUR","IE00BKPKM429.USD","BK4585","BK4588","NDAQ","LU0314104364.USD","BK4139","IE00B64PRP62.GBP","BK4112","MYNZ","LU2210149790.SGD"],"gpt_icon":0},{"id":"2572063611","title":"Mainz Biomed NV Enters Equity Distribution Agreement for Up to $10 Million in Ordinary Share Sales, Including $2.3 Million via Shelf Registration Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2572063611","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572063611?lang=en_us&edition=fundamental","pubTime":"2025-10-04 05:26","pubTimestamp":1759526786,"startTime":"0","endTime":"0","summary":"Mainz Biomed NV Enters Equity Distribution Agreement for Up to $10 Million in Ordinary Share Sales, Including $2.3 Million via Shelf Registration Statement. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mainz Biomed NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 03, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251003:nNDL5WWplZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MYNZ","BK4139"],"gpt_icon":0},{"id":"2571634291","title":"Mainz Biomed NV to Showcase Future of Colorectal Cancer Screening at World Endoscopy Organization Committee Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2571634291","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571634291?lang=en_us&edition=fundamental","pubTime":"2025-09-30 20:01","pubTimestamp":1759233690,"startTime":"0","endTime":"0","summary":"Mainz Biomed NV, a diagnostics company specializing in early cancer detection, will participate in the upcoming plenary session of the World Endoscopy Organization  Committee for Colorectal Cancer Screening on October 3, 2025, in Berlin. At the event, Dr. Lena Krammes, Senior Scientist at Mainz Biomed, will present the company's latest findings on RNA-based diagnostics for the detection and prevention of precancerous lesions, comparing early evidence from their RNA-based screening test to various FIT  cut-offs.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250930:nNDL5b8cWl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MYNZ","BK4139"],"gpt_icon":0},{"id":"2570830092","title":"Mainz Biomed Reports Financial Results for First Half of 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2570830092","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570830092?lang=en_us&edition=fundamental","pubTime":"2025-09-27 05:34","pubTimestamp":1758922492,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Mainz Biomed B.V. ( ($MYNZ) ). On September 26, 2025, Mainz Biomed N.V. released its Management’s Discussion an...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mainz-biomed-reports-financial-results-for-first-half-of-2025?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mainz-biomed-reports-financial-results-for-first-half-of-2025?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MYNZ","BK4139"],"gpt_icon":0},{"id":"2569909117","title":"Mainz Biomed announces commercial launch of ColoAlert in Switzerland","url":"https://stock-news.laohu8.com/highlight/detail?id=2569909117","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569909117?lang=en_us&edition=fundamental","pubTime":"2025-09-23 20:20","pubTimestamp":1758630027,"startTime":"0","endTime":"0","summary":"Mainz Biomed (MYNZ) announces the commercial launch of its flagship product, ColoAlert, in Switzerland. This milestone comes as the result of sever...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mainz-biomed-announces-commercial-launch-of-coloalert-in-switzerland-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mainz-biomed-announces-commercial-launch-of-coloalert-in-switzerland-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MYNZ","BK4139"],"gpt_icon":0},{"id":"2569972547","title":"Mainz Biomed NV Announces Launch of ColoAlert® in Switzerland and Advances in eAArly DETECT 2 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2569972547","media":"Reuters","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569972547?lang=en_us&edition=fundamental","pubTime":"2025-09-23 20:01","pubTimestamp":1758628902,"startTime":"0","endTime":"0","summary":"Mainz Biomed NV, a diagnostics company specializing in cancer early detection, has announced the commencement of the marketing of its primary product, ColoAlert, in Switzerland. This development marks a significant milestone following several key achievements by the company. Earlier this year, Mainz Biomed entered into a strategic partnership with labor team w ag, a leading diagnostics laboratory in Switzerland, to ensure the nationwide distribution of ColoAlert through an established and trusted network. The test has been officially registered and approved for distribution by Swissmedic, the Swiss agency for therapeutic products, enabling access to innovative colorectal cancer screening solutions for Swiss patients. In addition, a comprehensive technology transfer has been successfully completed, allowing the local processing and evaluation of ColoAlert samples in Goldach, Switzerland. Meanwhile, the company is advancing the recruitment for its feasibility study, which aims to include","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250923:nNDL2YvdJ3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MYNZ","BK4139"],"gpt_icon":0},{"id":"2565568298","title":"Mainz Biomed NV  expected to post a loss of $2.80 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2565568298","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565568298?lang=en_us&edition=fundamental","pubTime":"2025-09-05 20:34","pubTimestamp":1757075644,"startTime":"0","endTime":"0","summary":"Mainz Biomed NV  expected to post a loss of $2.80 a share - Earnings Preview Mainz Biomed NV MYNZ.OQ, MYNZ.O is expected to  report resultson September 8 for the period ending March 31 2025The Mainz H","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250905:nL8N3US0OR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MYNZ"],"gpt_icon":0},{"id":"2564253804","title":"Mainz Biomed Announces Regulatory Approval of ColoAlert for Distribution in the United Kingdom","url":"https://stock-news.laohu8.com/highlight/detail?id=2564253804","media":"Reuters","labels":["corporation","policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564253804?lang=en_us&edition=fundamental","pubTime":"2025-09-02 20:02","pubTimestamp":1756814538,"startTime":"0","endTime":"0","summary":"Mainz Biomed NV, a specialist in cancer early detection diagnostics, has announced that its ColoAlert test has received official registration from the Medicines and Healthcare products Regulatory Agency  in the United Kingdom. This milestone allows the test, which detects tumor DNA biomarkers in stool samples, to be distributed throughout the UK. This regulatory approval follows a technology partnership with EDX Medical Group plc and aims to complement existing colorectal cancer screening programs, enhancing accessibility and participation in early cancer detection efforts.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250902:nNDL4gSrTR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MYNZ","BK4139"],"gpt_icon":0},{"id":"2559604979","title":"Mainz Biomed NV Receives Swissmedic Approval for ColoAlert® Cancer Screening Test in Switzerland","url":"https://stock-news.laohu8.com/highlight/detail?id=2559604979","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559604979?lang=en_us&edition=fundamental","pubTime":"2025-08-13 20:03","pubTimestamp":1755086628,"startTime":"0","endTime":"0","summary":"Mainz Biomed NV, a diagnostics company specializing in cancer early detection, has announced that its non-invasive colorectal cancer screening test, ColoAlert, has been officially registered and granted marketing approval by Swissmedic, the Swiss agency for therapeutic products. This approval allows ColoAlert to be marketed in Switzerland, following a partnership with the Swiss diagnostic laboratory, labor team w ag. The test, which detects colorectal cancer tumor DNA and other biomarkers in stool samples with high sensitivity, aims to improve early detection and increase participation in screening programs in Switzerland, where less than half of the eligible population currently participates in such programs. This milestone is part of Mainz Biomed's broader strategy to expand access to reliable colorectal cancer early detection solutions.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250813:nNDL2XFlYt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MYNZ"],"gpt_icon":0},{"id":"2556338500","title":"Mainz Biomed Prices $3 million Follow-on Offering at $1.35 per Unit","url":"https://stock-news.laohu8.com/highlight/detail?id=2556338500","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556338500?lang=en_us&edition=fundamental","pubTime":"2025-08-04 23:11","pubTimestamp":1754320289,"startTime":"0","endTime":"0","summary":"Mainz Biomed  said Monday it has priced a $3 million follow-on offering of 2.2 million units comprising shares and warrants at an offer price of $1.35 per unit.Each unit will comprise one share or a prefunded warrant and one Series A warrant for the purchase of one and one-half shares, the company said.The Series A warrants are immediately exercisable at $1.35 per share and will expire five years from the issue date, Mainz Biomed said.Price: 1.41, Change: +0.08, Percent Change: +6.02","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MYNZ","BK4139"],"gpt_icon":0},{"id":"2556380398","title":"Mainz Biomed NV Announces $3.0 Million Follow-On Offering of Ordinary Shares and Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2556380398","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556380398?lang=en_us&edition=fundamental","pubTime":"2025-08-04 22:22","pubTimestamp":1754317358,"startTime":"0","endTime":"0","summary":"Mainz Biomed N.V., a molecular genetics diagnostic company focused on early cancer detection, announced the pricing of a $3.0 million follow-on offering. The offering includes 2,222,222 units, each comprising one ordinary share  and one Series A warrant to purchase one and a half ordinary shares. The units are priced at $1.35 each, with the Series A warrants exercisable at the same price, expiring five years from issuance. This offering is conducted under an SEC-approved registration statement, with Maxim Group LLC as the sole placement agent. The transaction is expected to close around August 5, 2025, subject to customary closing conditions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mainz Biomed NV published the original content ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250804:nNDLnpXXQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","BK4139","IE00B64PRP62.GBP","IE00BGHQF748.EUR","BK4588","NDAQ","BK4112","LU2210150020.SGD","LU2210149790.SGD","MYNZ","LU2095319765.USD","IE00B3QW5Z07.USD","LU0314104364.USD","BK4585"],"gpt_icon":0},{"id":"2555027253","title":"Mainz Biomed NV Files For Offering 1.5 Million Ordinary Units - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2555027253","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555027253?lang=en_us&edition=fundamental","pubTime":"2025-07-31 05:38","pubTimestamp":1753911523,"startTime":"0","endTime":"0","summary":"Mainz Biomed NV <4TO.F>::*MAINZ BIOMED NV FILES FOR OFFERING 1.5 MILLION ORDINARY UNITS - SEC FILING  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 30-JUL-202521:23:02 GMT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250730:nRSD5sfL0x:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MYNZ","BK4139"],"gpt_icon":0},{"id":"2553210945","title":"Mainz Biomed NV and CARE Partner to Enhance Colorectal Cancer Screening for German Health Insurers","url":"https://stock-news.laohu8.com/highlight/detail?id=2553210945","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553210945?lang=en_us&edition=fundamental","pubTime":"2025-07-23 20:01","pubTimestamp":1753272083,"startTime":"0","endTime":"0","summary":"Mainz Biomed N.V., a diagnostics company focused on early cancer detection, has announced a new collaboration with CARE diagnostica Laborreagenzien GmbH. This agreement will enhance colorectal cancer screening services by integrating Mainz Biomed's ColoAlert test into CARE's existing online-based screening concepts, which are already used by over 15 statutory health insurance companies in Germany. The ColoAlert test employs molecular genetic analysis of biomarkers in stool to improve detection rates, particularly in early stages. This cooperation aims to expand the distribution of ColoAlert in the German market, aligning with the increasing demand for personalized early intervention screening solutions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250723:nNDL6BWz1P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","LU2095319765.USD","NDAQ","IE00B3QW5Z07.USD","LU2210150020.SGD","BK4112","BK4585","MYNZ","IE00BKPKM429.USD","BK4588","IE00BGHQF748.EUR","BK4139","LU2210149790.SGD"],"gpt_icon":0},{"id":"2551162472","title":"Mainz Biomed NV Secures Government Funding for Innovative Pancreatic Cancer Screening Project from Rheinland-Pfalz Development Bank","url":"https://stock-news.laohu8.com/highlight/detail?id=2551162472","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551162472?lang=en_us&edition=fundamental","pubTime":"2025-07-15 20:02","pubTimestamp":1752580927,"startTime":"0","endTime":"0","summary":"Mainz Biomed NV Secures Government Funding for Innovative Pancreatic Cancer Screening Project from Rheinland-Pfalz Development Bank. Mainz Biomed NV has announced that its pancreatic cancer project will receive public funding from the Investitions- und Strukturbank Rheinland-Pfalz , the development bank of the German federal state of Rheinland-Pfalz. Under the ISB's Innovation and Technology Support Program, the state will fund up to 50% of the project's total costs. This governmental support highlights the scientific and societal value of the company's non-invasive, blood-based screening test for early pancreatic cancer detection, and is expected to accelerate its development. The funding is specifically for Mainz Biomed, and there is no indication of multiple organizations receiving this grant.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250715:nNDL1dCyMc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MYNZ","BK4139"],"gpt_icon":0},{"id":"2551164423","title":"Mainz Biomed Half Year 2025 Update: Accelerating FDA Pathway for NextGen Colorectal Cancer Screening and Expansion with Pancreatic Cancer Screening Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2551164423","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551164423?lang=en_us&edition=fundamental","pubTime":"2025-07-15 20:01","pubTimestamp":1752580860,"startTime":"0","endTime":"0","summary":"Company Advances its Progress toward FDA Premarket Approval Study for its Next Generation Colorectal Cancer Screening Product and Makes a Strategic Acquisition in theField of Pancreatic Cancer Screeni","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/15/3115553/0/en/Mainz-Biomed-Half-Year-2025-Update-Accelerating-FDA-Pathway-for-NextGen-Colorectal-Cancer-Screening-and-Expansion-with-Pancreatic-Cancer-Screening-Acquisition.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MYNZ","NGCAU"],"gpt_icon":0}],"profile":{"websiteUrl":"http://mainzbiomed.com","stockEarnings":[{"period":"1week","weight":0.0741},{"period":"1month","weight":-0.1831},{"period":"3month","weight":-0.2883},{"period":"6month","weight":-0.441},{"period":"1year","weight":-0.8292},{"period":"ytd","weight":-0.7315}],"compareEarnings":[{"period":"1week","weight":0.0034},{"period":"1month","weight":0.012},{"period":"3month","weight":0.0594},{"period":"6month","weight":0.1445},{"period":"1year","weight":0.1303},{"period":"ytd","weight":0.17}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.172125},{"month":2,"riseRate":0.25,"avgChangeRate":-0.062234},{"month":3,"riseRate":0.5,"avgChangeRate":-0.077229},{"month":4,"riseRate":0.25,"avgChangeRate":-0.148679},{"month":5,"riseRate":0.25,"avgChangeRate":-0.028304},{"month":6,"riseRate":0,"avgChangeRate":-0.291752},{"month":7,"riseRate":0.75,"avgChangeRate":0.072818},{"month":8,"riseRate":0,"avgChangeRate":-0.153442},{"month":9,"riseRate":0,"avgChangeRate":-0.167388},{"month":10,"riseRate":0.25,"avgChangeRate":-0.076172},{"month":11,"riseRate":0.25,"avgChangeRate":-0.142413},{"month":12,"riseRate":0.6,"avgChangeRate":-0.108269}],"exchange":"NASDAQ","name":"Mainz Biomed B.V.","nameEN":"Mainz Biomed B.V."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Mainz Biomed B.V.(MYNZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Mainz Biomed B.V.(MYNZ) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Mainz Biomed B.V.,MYNZ,Mainz Biomed B.V.股票,Mainz Biomed B.V.股票老虎,Mainz Biomed B.V.股票老虎国际,Mainz Biomed B.V.行情,Mainz Biomed B.V.股票行情,Mainz Biomed B.V.股价,Mainz Biomed B.V.股市,Mainz Biomed B.V.股票价格,Mainz Biomed B.V.股票交易,Mainz Biomed B.V.股票购买,Mainz Biomed B.V.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Mainz Biomed B.V.(MYNZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Mainz Biomed B.V.(MYNZ) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction